Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells

Journal of Immunology

Volumn 180, Issue 5, 2008, Pages 3122-3131

  Wong, S B Justin ^a   Bos, Rinke ^a   Sherman, Linda A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN; VACCINE; CANCER VACCINE; EPITOPE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER INVASION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL CYCLE PHASE; CELL EXPANSION; CELL INFILTRATION; CELL SPECIFICITY; CLONAL VARIATION; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOID TISSUE; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; TUMOR CELL DESTRUCTION; ADOPTIVE TRANSFER; ANIMAL; CELL CLONE; CELL MOTION; COMPARATIVE STUDY; GENETICS; IMMUNOLOGY; INSULINOMA; LYMPHOCYTE ACTIVATION; PANCREAS TUMOR; PATHOLOGY; RAT; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CLONE CELLS; EPITOPES, T-LYMPHOCYTE; INSULINOMA; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; PANCREATIC NEOPLASMS; RATS;

EID: 49149130306     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.5.3122     Document Type: Article

References (63)

1. Theobald, M., J. Biggs, J. Hernandez, J. Lustgarten, C. Labadie, and L. A. Sherman. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185: 833-841.
2. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182: 18-32.
3. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95: 1178-1183.
4. Hirano, F., K. Kaneko, H. Tamura, H. Dong, S. Wang, M. Ichikawa, C. Rietz, D. B. Flies, J. S. Lau, G. Zhu, et al. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65: 1089-1096.
5. + T cells in patients with melanoma. J. Immunol. 175: 6169-6176.
6. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321-327.
7. Mukai, S., J. Kjaergaard, S. Shu, and G. E. Plautz. 1999. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res. 59: 5245-5249.
8. Ganss, R., E. Ryschich, E. Klar, B. Arnold, and G. J. Hammerling. 2002. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62: 1462-1470.
9. Lugade, A. A., J. P. Moran, S. A. Gerber, R. C. Rose, J. G. Frelinger, and E. M. Lord. 2005. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174: 7516-7523.
10. Morales, A., D. Eidinger, and A. W. Bruce. 1976. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 116: 180-183.
11. Scheel, B., S. Aulwurm, J. Probst, L. Stitz, I. Hoerr, H. G. Rammensee, M. Weller, and S. Pascolo. 2006. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur. J. Immunol. 36: 2807-2816.
12. + T cells. Immunity 22: 371-383.
13. + T cells in the antitumor immune response. J. Exp. Med. 188: 2357-2368.
14. + tumor-specific Th1 cells colocalize with and inhibit development and growth of murine neoplasms. J. Immunol. 174: 1405-1415.
15. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells. Immunity 12: 677-686.
16. Ossendorp, F., E. Mengede, M. Camps, R. Filius, and C. J. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187: 693-702.
17. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol. 165: 6047-6055.
18. + Tc1 tumor localization and therapy. Gene Ther. 12: 999-1010.
19. + T cells: when, where, and how. Annu. Rev. Immunol. 24: 519-540.
20. Guermonprez, P., J. Valladeau, L. Zitvogel, C. Thery, and S. Amigorena. 2002. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20: 621-667.
21. Janeway, C. A., and R. Medzhitov. 2002. Innate immune recognition. Annu. Rev. Immunol. 20: 197-216.
22. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12: 991-1045.
23. + T cell immunity. Nat. Immunol. 5: 1143-1148.
24. + T-helper and a T-killer cell. Nature 393: 474-478.
25. + T lymphocytes. Nature 421: 852-856.
26. Shedlock, D. J., and H. Shen. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300: 337-339.
27. Sun, J. C., and M. J. Bevan. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300: 339-342.
28. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434: 88-93.
29. Behrens, G., M. Li, C. M. Smith, G. T. Belz, J. Mintern, F. R. Carbone, and W. R. Heath. 2004. Helper T cells, dendritic cells and CTL immunity. Immunol. Cell Biol. 82: 84-90.
30. + T lymphocytes into effector CTL. J. Immunol. 172: 6558-6567.
31. Mackett, M., G. L. Smith, and B. Moss. 1984. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 49: 857-864.
32. + T cells in tumor-bearing mice. J. Immunol. 174: 2563-2572.
33. Keene, J. A., and J. Forman. 1982. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155: 768-782.
34. + T cells. Eur. J. Immunol. 22: 1013-1022.
35. Boissonnas, A., L. Fetler, I. S. Zeelenberg, S. Hugues, and S. Amigorena. 2007. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J. Exp. Med. 204: 345-356.
36. Matzinger, P. 2002. The danger model: a renewed sense of self. Science 296: 301-305.
37. + T cells. Immunol. Cell Biol. 67: 413-420.
38. Shedlock, D. J., J. K. Whitmire, J. Tan, A. S. MacDonald, R. Ahmed, and H. Shen. 2003. Role of CD4 T cell help and costimulation in CD8 T cell responses during Listeria monocytogenes infection. J. Immunol. 170: 2053-2063.
39. + T lymphocytes. J. Immunol. 151: 5993-6001.
40. Gajewski, T. F., Y. Meng, C. Blank, I. Brown, A. Kacha, J. Kline, and H. Harlin. 2006. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213: 131-145.
41. Zou, W. 2005. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
42. Garbi, N., B. Arnold, S. Gordon, G. J. Hammerling, and R. Ganss. 2004. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 172: 5861-5869.
43. Masopust, D., V. Vezys, A. L. Marzo, and L. Lefrancois. 2001. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291: 2413-2417.
44. + T cells. Immunol. Rev. 186: 221-233.
45. Chakraverty, R., D. Cote, J. Buchli, P. Cotter, R. Hsu, G. Zhao, T. Sachs, C. M. Pitsillides, R. Bronson, T. Means, et al. 2006. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J. Exp. Med. 203: 2021-2031.
46. Darabi, K., A. Y. Karulin, B. O. Boehm, H. H. Hofstetter, Z. Fabry, J. C. LaManna, J. C. Chavez, M. Tary-Lehmann, and P. V. Lehmann. 2004. The third signal in T cell-mediated autoimmune disease? J. Immunol. 173: 92-99.
47. Lang, K. S., M. Recher, T. Junt, A. A. Navarini, N. L. Harris, S. Freigang, B. Odermatt, C. Conrad, L. M. Ittner, S. Bauer, et al. 2005. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 11: 138-145.
48. Vezys, V., and L. Lefrancois. 2002. Cutting edge: inflammatory signals drive organ-specific autoimmunity to normally cross-tolerizing endogenous antigen. J. Immunol. 169: 6677-6680.
49. Campbell, I. L., T. W. Kay, L. Oxbrow, and L. C. Harrison. 1991. Essential role for interferon-γ and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J. Clin. Invest. 87: 739-742.
50. Christen, U., D. B. McGavern, A. D. Luster, M. G. von Herrath, and M. B. Oldstone. 2003. Among CXCR3 chemokines, IFN-γ-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-γ (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. J. Immunol. 171: 6838-6845.
51. Debray-Sachs, M., C. Carnaud, C. Boitard, H. Cohen, I. Gresser, P. Bedossa, and J. F. Bach. 1991. Prevention of diabetes in NOD mice treated with antibody to murine IFNγ. J. Autoimmun. 4: 237-248.
52. Savinov, A. Y., F. S. Wong, and A. V. Chervonsky. 2001. IFN-γ affects homing of diabetogenic T cells. J. Immunol. 167: 6637-6643.
53. + cells in pancreatic islets of NOD mice. Diabetes 40: 648-651.
54. Frigerio, S., T. Junt, B. Lu, C. Gerard, U. Zumsteg, G. A. Hollander, and L. Piali. 2002. β cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat. Med. 8: 1414-1420.
55. Rolph, M. S., and S. H. Kaufmann. 2001. CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes. J. Immunol. 166: 5115-5121.
56. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
57. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5: 780-787.
58. Diehl, L., A. T. den Boer, S. P. Schoenberger, E. I. van der Voort, T. N. Schumacher, C. J. Melief, R. Offringa, and R. E. Toes. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5: 774-779.
59. + T cell memory. Science 297: 2060-2063.
60. + T cells after infection. Nat. Immunol. 3: 619-626.
61. Schober, S. L., C. T. Kuo, K. S. Schluns, L. Lefrancois, J. M. Leiden, and S. C. Jameson. 1999. Expression of the transcription factor lung Kruppel-like factor is regulated by cytokines and correlates with survival of memory T cells in vitro and in vivo. J. Immunol. 163: 3662-3667.
62. + T cells. J. Exp. Med. 186: 239-245.
63. + T cells undergo peripheral tolerance. Immunity 17: 73-81.